Stock AEVI GENOMIC MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Aevi Genomic Medicine, Inc. Stock

Equities

US00835P1057

Biotechnology & Medical Research

Chart Aevi Genomic Medicine, Inc.

Dynamic Chart

Latest news about Aevi Genomic Medicine, Inc.

Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index CI
Aevi Genomic Medicine, Inc. Announces Resignation of Directors CI
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index CI
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc.. CI
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million. CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18) CI
Declaration of Voting Results by Aevi Genomic Medicine, Inc. CI
Aevi Genomic Medicine, Inc. Announces Executive Changes CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
The Children’s Hospital Nominates Board Candidate to Aevi Genomic CI
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Aevi Genomic Medicine, Inc. Auditor Raises 'Going Concern' Doubt CI
More news

Press releases Aevi Genomic Medicine, Inc.

AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) AQ
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K) AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A) AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) AQ
More press releases

Company Profile

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. Stock